Product Description
Amgen is developing conatumumab, a monoclonal antibody agonist directed against Death Receptor 5, for the treatment of cancer and tumors. (Sourced from: https://investors.amgen.com/news-releases/news-release-details/amgens-oncology-pipeline-data-highlighted-upcoming-scientific)
Mechanisms of Action: TNFS10B Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, Germany, Italy, Korea, Netherlands, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Abnormalities, Multiple|Colorectal Cancer|Hodgkin Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Oncology Solid Tumor Unspecified|Sarcoma|Vision, Low
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2031210121 |
jRCT2031210121 | P2 |
Recruiting |
Sarcoma |
2029-01-14 |
|||
2024-515144-23-00 |
GO45416 | P2 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2028-05-31 |
2025-05-02 |
Treatments |
|
NCT02925234 |
DRUP | P2 |
Recruiting |
Hodgkin Lymphoma|Vision, Low|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Abnormalities, Multiple |
2027-09-01 |
12% |
2024-01-25 |
Primary Endpoints |
2018-001600-12 |
VELO | P2 |
Completed |
Colorectal Cancer |
2024-10-12 |
2025-05-06 |
Treatments|Trial Status |
|
2018-001210-15 |
RASmiR | P2 |
Active, not recruiting |
Colorectal Cancer |
2022-10-10 |
2022-03-13 |
Treatments |